Skip to main content

Danaher Corporation (DHR-PB)

New York Stock Exchange Healthcare Medical - Diagnostics & ResearchView data quality →
50.1Fair

ValueMarkers Composite Index

Top 29%#31,723 of 44,714

DCF data not available

Piotroski
6/9
Neutral
Beneish
-2.76
Low Risk
Altman
19.15
Safe
DCF Value
-
N/A
ROIC
5.7%
Low
P/E
38.3
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Danaher Corporation (DHR-PB) — VMCI valuation read

The headline on Danaher Corporation (DHR-PB) is a 50/100 VMCI score, set against a Healthcare sector median of 50. That 0-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

DHR-PB insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** DHR-PB trades at 17.0x earnings, 6% below the Healthcare median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 0.8x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on DHR-PB.

DHR-PB rose 1.6% over the trailing 7 days, with a +2.6% read on a 30-day basis.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

CEO: Rainer M. Blair79,000 employeesUSwww.danaher.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in DHR-PB’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.